Scientists from St. Luisi University of Washington and Sweden have created a blood test that not only helps to discover Alzheimer's disease, but also determines the speed of its progress. The results of the study were published in Nature Medicine.
Alzheimer's disease is a neurodegenerative disease, during which Amyloid beta protein aggregates and so-called fibers appear in the brain. Existing blood tests can detect the existence of beta-amyloid, but there was no simple way to find the accumulation of the Tau Protein.
Scientists have completed the gap of this knowledge by focusing on MTBR-TAU243 protein. According to researchers, the concentration of MTBR-TAU243 in the blood plasma is directly related to the number of accumulations of the protein in the brain. The analysis has shown that MTBR-TAU243 reflects the number of tau aggregates with 92% accuracy.
The team also analyzed the blood samples of people with cognitive disorders and found that MTBR-TAU243 levels clearly differ in the early and late stages of Alzheimer's disease. The level of MTBR-TAU243 is slightly climbing with light symptoms and has been increased 200 times in people with heavy demil.
"MTBR-TAU243 Analysis will be a very valuable addition to both clinical settings and research. When two biomarkers (MTBR-TAU243 and P-TAU217) are positive, the probability that Alzheimer's disease is a reason for cognitive disorder increases significantly. This difference is important to select appropriate treatment for each patient.
Translation of: Euromedia24.com
